Your browser does not support JavaScript! before use docindia please enable Javascript on your browser

Adenosine Injection, USPFOR RAPID BOLUS INTRAVENOUS USE


DESCRIPTION


CLINICAL PHARMACOLOGY


Mechanism of Action


Hemodynamics


Pharmacokinetics


Clinical Trial Results


INDICATIONS AND USAGE

Intravenous adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.  It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION).1Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.  In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration.


CONTRAINDICATIONS

  • Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker).
  • Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
  • Known hypersensitivity to adenosine.

WARNINGS


Heart Block


Arrhythmias at Time of Conversion


Bronchoconstriction


PRECAUTIONS


Drug Interactions


Carcinogenesis, Mutagenesis, Impairment of Fertility


Pregnancy Category C


Pediatric Use


Geriatric Use


ADVERSE REACTIONS


Cardiovascular


Respiratory


Central Nervous System


Gastrointestinal


Post Marketing Experience (see WARNINGS)


Cardiovascular


Respiratory


Central Nervous System


OVERDOSAGE


DOSAGE AND ADMINISTRATION


Adult Patients


Pediatric Patients


HOW SUPPLIED

  • Paul T, Pfammatter. J-P. Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatric Cardiology 1997; 18:118-126. 

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL